Profit before payment of interest, taxes and amortization: singulargenomics.com (OMIC)
Singular Genomics Systems (OMIC) cash flows depend on R&D cycles and quarterly procurement, while consumables mitigate macro shocks. Monthly EBITDA dynamics confirm this trend, where the value of captures the metric level. However, pricing pressure and the erosion of benchtop system advantages are hindering growth, while the dominance of tech giants and service costs create significant business risks.
Singular Genomics (OMIC) - metric breakdowns and financial figures
- market price and analyst price targets:
- company stock exchange capitalization indicators:
- business book valuation details:
- business debt structure and liquidity details:
All Debt to Shareholders' Equity Ratio Singular Genomics Systems|OMIC - Long-Term Debt to Capital|Short-Term Indebtedness to Equity Singular Genomics Systems, Inc.|OMIC - Company Aggregate Debts|Debts to Book Value Singular Genomics|OMIC - Company Long-Term Debt|Company Short-Term Indebtedness Singular Genomics|Immediate Liquidity singulargenomics.com
- business earnings and investment ratios data:
OMIC - Company Net Income|Future Profit Singular Genomics Systems|OMIC - P/E Multiple|Market Cap to Projected Earnings singulargenomics.com|OMIC - PEG Multiple|Enterprise Value to EBITDA Ratio Singular Genomics|OMIC - Profit before payment of interest, taxes and amortization|Net earnings per share for the last four quarters Singular Genomics|OMIC - Net earnings per share for the last 12 months|Year-over-year earnings per one share growth for the last 12 months singulargenomics.com|OMIC - Earnings per share growth in current year|Consensus forecast of earnings per share growth for next year Singular Genomics Systems
Summary company analytics:Singular Genomics Systems
The market values Singular Genomics Systems (OMIC) through the lens of the implementation efficiency of sustainable genomic technologies that reduce energy costs and reagent consumption. Monitoring operating profit in cash terms allows for a real-time assessment to eliminate accounting lags by measuring the actual liquidity inflow from the core business, which is critical for confirming the company's stability regardless of one-off inventory transactions.
Competitors of Singular Genomics Systems (OMIC)
Operating profit EBITDA Tempus TEM|QGEN - Profit before payment of interest, taxes and amortization|IONS: Profit before payment of interest, taxes and amortization|RGEN: Operating profit EBITDA|Avidity Biosciences Inc (RNA) - Operating profit EBITDA|Profit before payment of interest, taxes and amortization CRISPR Therapeutics Corp|WGS: Income before deduction of interest, taxes and amortization|Operating profit before deduction of amortization RARE (Ultragenyx Pharmaceutical)|BEAM (beamtx.com) - Income before deduction of interest, taxes and amortization|Operating profit EBITDA SRPT (Sarepta)|Operating profit before depreciation charges Twist Bioscience Inc|10x Genomics Corp - Operating profit EBITDA|Profit before interest, taxes and amortization Intellia Corp|Stoke Therapeutics (STOK) - Profit before payment of interest, taxes and amortization|Operating profit before amortization BLFS|Profit before payment of interest, taxes and amortization Wave Life Sciences Ltd.|Profit before interest, taxes and amortization Maze Therapeutics, Inc. MAZE|Profit before payment of interest, taxes and amortization Sionna Pharma (SION)|Operating profit before deduction of amortization Prime Medicine Bio PRME|Operating profit EBITDA TSHA (Taysha Gene Therapies)|Operating income before deduction of amortization uniqure.com (QURE)|MeiraGTx - Operating profit EBITDA|REGENXBIO Inc (RGNX) - Operating profit before deduction of amortization|Solid Bio (SLDB) - Profit before payment of interest, taxes and amortization|OCGN - Operating income before deduction of amortization|Operating profit before deduction of amortization PACB|BNTC: Income before deduction of interest, taxes and amortization|Profit before payment of interest, taxes and amortization Design Therapeutics, Inc. (DSGN)|Operating income before deduction of amortization Rocket Pharma|4D Molecular Therapeutics Inc - Operating profit before deduction of amortization|Lexeo Therapeutics Inc. (LXEO) - Profit before interest, taxes and amortization|KRRO - Profit before payment of interest, taxes and amortization|Operating income before deduction of amortization editasmedicine.com EDIT|SLN (Silence Therapeutics plc) - Operating profit before deduction of amortization|PRQR: Company profit before taxes, interest and amortization|CDXS (Codexis Inc) - Operating profit EBITDA|Profit before interest, taxes and amortization Sangamo BioSciences SGMO|Profit before payment of interest, taxes and amortization Nautilus Biotechnology (NAUT)|Operating profit before deduction of amortization metagenomi.co MGX|Profit before payment of interest, taxes and amortization Precision BioSciences, Inc. DTIL|Operating income before deduction of amortization Generation Bio Co (GBIO)|BOLD - Profit before payment of interest, taxes and amortization|Profit before interest, taxes and amortization Exicure, Inc.|imunon.com (IMNN) - Profit before payment of interest, taxes and amortization|Operating profit before deduction of amortization Phio Pharmaceuticals Corp.|MBIO (Mustang Bio Inc) - Operating profit EBITDA|TransCode (RNAZ) - Operating income before deduction of amortization|Operating profit EBITDA BNGO|Operating profit before deduction of amortization Applied DNA Corp APDN|Operating profit EBITDA BLUE (bluebird bio, Inc.)|IPA: Operating profit before amortization|OMGA - Profit before payment of interest, taxes and amortization|RGLS (Regulus Therapeutics, Inc.) - Operating profit before amortization|SYRS: Operating profit EBITDA|Telesis Bio, Inc (TBIO) - Operating profit EBITDA|Profit before payment of interest, taxes and amortization TRACON Pharmaceuticals|unitybiotechnology.com (UBX) - Operating income before deduction of amortization
